Ignite Creation Date:
2024-05-05 @ 5:18 PM
Last Modification Date:
2024-10-26 @ 9:30 AM
Study NCT ID:
NCT00421642
Status:
COMPLETED
Last Update Posted:
2012-08-01
First Post:
2007-01-11
Brief Title:
Open-Label Adalimumab for Ulcerative Colitis Patients
Sponsor:
Mayo Clinic
Organization:
Mayo Clinic
Study Overview
Official Title:
An Open-Label Study of the Human Anti-TNF Monoclonal Antibody Adalimumab in Ulcerative Colitis Patients
Status:
COMPLETED
Status Verified Date:
2012-07
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This is an open-label study of 20 patients designed to demonstrate the safety tolerability and preliminary evidence of benefit of adalimumab in the treatment of subjects with Ulcerative Colitis both in patients who have never received anit-TNF agents and in those who have lost response or developed intolerance to previous infliximab therapy
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None